Gubra Past Earnings Performance
Past criteria checks 0/6
Gubra's earnings have been declining at an average annual rate of -100.6%, while the Life Sciences industry saw earnings growing at 19.6% annually. Revenues have been growing at an average rate of 1% per year.
Key information
-100.6%
Earnings growth rate
-110.5%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 1.0% |
| Return on equity | -9.3% |
| Net Margin | -21.7% |
| Next Earnings Update | 23 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gubra makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 205 | -45 | 75 | 89 |
| 30 Sep 23 | 204 | -26 | 73 | 83 |
| 30 Jun 23 | 204 | -7 | 71 | 77 |
| 31 Mar 23 | 201 | -1 | 69 | 67 |
| 31 Dec 22 | 199 | 4 | 67 | 57 |
| 31 Dec 21 | 255 | 68 | 52 | 27 |
| 31 Dec 20 | 172 | 13 | 45 | 34 |
Quality Earnings: GUBRAC is currently unprofitable.
Growing Profit Margin: GUBRAC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GUBRAC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GUBRAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GUBRAC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.7%).
Return on Equity
High ROE: GUBRAC has a negative Return on Equity (-9.28%), as it is currently unprofitable.